Catalyst Health Economics Consultants

Cow’s Milk Allergy

1. Modelling the resource implications and budget impact of new reimbursement guidelines for the management of cow milk allergy in Finland.

Authors: JF Guest & E Valovirta.
Source: Current Medical Research and Opinion 2008; 24(4): 1167-1177.

View Abstract


2. Budget impact of managing cow milk allergy in Australia.

Presented at the 2nd International Conference of the Asia Pacific Society for Healthcare Quality in Singapore, January 2008

View pdf


3. Management of cow milk allergy in the UK.

Presented at the Annual Meeting of the British Society for Allergy & Clinical Immunology, in Loughborough, UK, July 2008 and the World Congress of Paediatric Gastroenterology, Hepatology and Nutrition (WCPGHAN) in Brazil, August 2008.


4. Budget impact of managing cow milk allergy in the UK.

Presented at the Annual Meeting of the British Society for Allergy & Clinical Immunology, in Loughborough, UK, July 2008 and the World Congress of Paediatric Gastroenterology, Hepatology and Nutrition (WCPGHAN) in Brazil, August 2008.


5. Modelling the resource implications and budget impact of managing cow milk allergy in Australia.

Authors: JF Guest & E Nagy.
Source: Current Medical Research and Opinion 2009; 25(2): 339-349

View Abstract


6. Resource implications and budget impact of managing cow milk allergy in the UK.

Authors: E Sladkevicius, E Nagy, G Lack & JF Guest.
Source: Journal of Medical Economics 2010; 13(1): 119-128.

View Abstract


7. Budget impact of managing cow milk allergy in the Netherlands.

Authors: E Sladkevicius & JF Guest.
Source: Journal of Medical Economics 2010; 13(2): 273-283.

View Abstract


8. Modelling the health economic impact of managing cow milk allergy in South Africa.

Authors: E Sladkevicius & JF Guest.
Source: Journal of Medical Economics 2010; 13(2): 257-272.

View Abstract

9. Cost-effectiveness of using an extensively hydrolysed formula compared to an amino acid formula as first-line treatment for cow milk allergy in the United Kingdom.

Presented at the 44th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN), Sorrento, May 2011 and the 30th congress of the European Academy of Allergy and Clinical Immunology (EAACI), Istanbul, June 2011

View pdf

10. Cost-effectiveness of using an extensively hydrolysed formula compared to an amino acid formula as first-line treatment for cow milk allergy in the UK.

Authors: RR Taylor, E Sladkevicius, M Panca, G Lack, JF Guest.
Source: Pediatric Allergy and Immunology 2012; 23(3):240-249.

View Abstract

11. Cost-effectiveness of using Nutramigen extensively hydrolysed formula compared to Neocate amino acid formula as first-line management for cow milk allergy in the U.S.

Presented at the 2014 Joint Meeting of the Pediatric Academic Societies (PAS) and Asian Society for Pediatric Research, Vancouver, May 2014.

12. Relative cost-effectiveness of an extensively hydrolyzed casein formula plus the probiotic Lactobacillus Rhamnosus GG in the management of infants with cow’s milk allergy in Italy.

Presented at the 47th Annual Meeting of the European Society for Paediatric Gastroenterology, Hepatology, and Nutrition (ESPGHAN), Jerusalem, June 2014.

13. Health economic implications of cow’s milk protein allergy.

Presented at a specially convened symposium for “Allergy Day”, Madrid, October 2014.

14. Health economic implications of cow’s milk protein allergy.

Presented at a specially convened symposium on Paediatric Food Allergy, Rio de Janeiro, November 2014.

15. Cost-effectiveness of using an extensively hydrolysed casein formula plus the probiotic Lactobacillus rhamnosus GG compared to an extensively hydrolysed formula alone or an amino acid formula as first-line dietary management for cow’s milk allergy in the US.

Authors: O Ovcinnikova, M Panca, JF Guest.
Source: Clinicoeconomics and Outcomes Research 2015;7:145-52. doi: 10.2147/CEOR.S75071.

View Abstract

16. Relative cost-effectiveness of an extensively hydrolysed casein formula containing the probiotic Lactobacillus rhamnosus GG in managing infants with cow’s milk allergy in Italy.

Authors: JF Guest, M Panca, O Ovcinnikova, R Nocerino.
Source: Clinicoeconomics and Outcomes Research 2015;7 325–336.

View Abstract

17. Relative cost-effectiveness of using an extensively hydrolysed casein formula containing the probiotic Lactobacillus rhamnosus GG in managing infants with cow’s milk allergy in Spain.

Authors: JF Guest, D Weidlich, JI Mascuñan Díaz, JJ Díaz, PM Ojeda, JP Ferrer-Gonzalez, D Gil, I Onrubia, P Rincón Victor.
Source: Clinicoeconomics and Outcomes Research 2015:7 583–591.

View Abstract

18. Relative cost-effectiveness of using an extensively hydrolysed casein formula containing the probiotic Lactobacillus rhamnosus GG in managing infants with cow’s milk allergy in Poland.

Authors: JF Guest, D Weidlich, M Kaczmarski, E Jarocka-Cyrta, N Kobelska-Dubiel, A Krauze, I Sakowska-Maliszewska, A Zawadzka-Krajewska.
Source: Clinicoeconomics and Outcomes Research 2016: 28;8:307-16. doi: 10.2147/CEOR.S105748.

View Abstract

19. Relative cost-effectiveness of using an extensively hydrolyzed casein formula in managing infants with cow’s milk allergy in Brazil.

Authors: JF Guest, AC Yang, J Oba, M Rodrigues, R Caetano, L Polster.
Source: Clinicoeconomics and Outcomes Research 2016; 8: 629–639.

View Abstract

20. Cost-effectiveness of using an extensively hydrolysed casein formula containing Lactobacillus rhamnosus GG in managing infants with cow’s milk allergy in the US.

Authors: JF Guest, RH Kobayashi, V Mehta, G Neidich.
Source: Current Medical research & Opinion 2017; doi: 10.1080/03007995.2017.1400962

View Abstract


<<< Go Back

Catalyst Health Economics Consultants Ltd
© 1991 - 2018